Emerging Therapeutic Strategies for Drug-induced Pulmonary Injury: A Mini Review

Drug-induced pulmonary injury (DIPI) represents a significant, though often under-recognized, complication of pharmacotherapy. With the increasing global use of chemotherapeutic agents, immunomodulators, and novel biologics, the reported incidence of DIPI is rising, thereby posing significant diagnostic and management challenges. This mini-review outlines the mechanisms, clinical manifestations, and current treatment approaches for DIPI, while highlighting recent advances in biomarker discovery and targeted interventions. This review emphasizes early detection and personalized management to mitigate morbidity and mortality associated with this condition.